Next Article in Journal
Influence of Enzymatic Acylation on the Stability and Antioxidant Properties of Cyanidin-3-O-Glucoside in Both Aqueous and Lipid Systems
Previous Article in Journal
Comparative Analysis of Lespedeza Species: Traditional Uses and Biological Activity of the Fabaceae Family
Previous Article in Special Issue
Microwave-Assisted Enantioselective Synthesis of (2R,5S)-Theaspirane: A Green Chemistry Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 30
Issue 9
10.3390/molecules30092014
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of 1,4-Benzodiazepines via Intramolecular C–N Bond Coupling and Ring Opening of Azetidines

by
Xin-Ming Xu
1,*,
Sen Chen
1,
Shao-Lei Duan
1,
Xiang-Min Wang
1,
Qian Liu
2 and
Kai Sun
1,*
1
School of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China
2
School of Life Scienses, Yantai University, Yantai 264005, China
*
Authors to whom correspondence should be addressed.
Molecules 2025, 30(9), 2014; https://doi.org/10.3390/molecules30092014
Submission received: 25 March 2025 / Revised: 28 April 2025 / Accepted: 29 April 2025 / Published: 30 April 2025
(This article belongs to the Special Issue Synthesis, Modification and Application of Heterocyclic Compounds)
Browse Figures
Versions Notes

Abstract

:
A facile and efficient synthesis of functionalized 1,4-benzodiazepine derivatives under mild conditions was developed. The CuI/N,N-dimethylglycine-catalyzed intramolecular cross-coupling reaction of 1-(2-bromobenzyl)azetidine-2-carboxamides proceeded smoothly under mild conditions to provide 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-ones. The resulting azetidine-fused 1,4-benzodiazepine compounds underwent consecutive N-methylation with methyl triflate and the opening of the four-membered heterocyclic ring by NaN3, KCN and PhSNa to produce diverse 1,4-benzodiazepine derivatives in good to excellent yields. Upon treatment with methyl chloroformate, on the other hand, the 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-ones were straightforwardly converted into 2-chloroethyl-substituted 1,4-benzodiazepine derivatives.

1. Introduction

1,4-Benzodiazepine is a privileged scaffold widely existing in natural products and biologically active compounds [1,2,3]. 1,4-Benzodiazepine derivatives are of significant interest in medicinal and pharmaceutical research because they exhibit a diverse range of biological activities, and some of them have been used in the clinical treatment of diseases [4]. For instance, diazepam A is the core structure of anxiolytics [5], anticonvulsants and hypnotics [6,7], and it is also an important fragment of some potential antiarrhythmics [8] and anti-HIV agents (Figure 1) [9]. Dibenzepin B, on the other hand, is a widely prescribed antidepressant drug [10], while compound D is used for the treatment of peptic ulcer disease [11]. In addition, some other 1,4-benzodiazepines also show antitumor (anthramycin C) [12,13], anticholinesterase (compound E) [14] and endothelin receptor antagonism activity (compound F) [15].
As a consequence, the synthesis of 1,4-benzodiazepines has been attracting much attention from organic and medicinal chemists, and a variety of synthetic approaches to 1,4-benzodiazepine skeletons have been developed. The documented methods can be generally classified into the following five protocols [16]. As summarized in Figure 2, the most frequently used methods are the reaction of 2-aminobenzaldehyde, 2-aminophenone or 2-aminobenzoic acid and their derivatives 1 with α-amino acid (path a) [17,18,19,20,21,22,23], the cyclocondensation of 2-amino- or 2-nitrobenzyl halogen or alcohol 2 with amino acid derivatives (path b) [24,25,26,27] and the reaction between diamines 3 and bis-electrophiles (path c) [28,29,30,31]. The Pd-catalyzed C–N coupling reaction of N-allyl-2-aminobenzyl-/benzoylamines 4 [32,33,34,35] and the amidation of aromatic compounds 5 [36,37,38] provide other useful routes to the 1,4-benzodiazepine structure (paths d and e). However, most of the existing methods can only construct 1,4-benzodiazepines without a functional group at the 2- and 3-positions. To further search for 1,4-benzodiazepine molecules with potential biological activity for drug discovery, it is highly desirable and imperative to develop new methods for the facile construction of novel and functionalized 1,4-benzodiazepine derivatives.
Inspired by Wang’s previous work [39], we envisaged that the intramolecular cross-coupling reaction of 1-(2-bromobenzyl)azetidine-2-carboxamides 6 would provide a general method for the synthesis of novel azetidine-fused 1,4-diazepine derivatives 7 (Scheme 1). Moreover, the resulting products would be an invaluable platform for the preparation of functionalized 1,4-benzodiazepine derivatives 9 based on the opening of the azetidine ring by nucleophiles. We report herein the facile construction of 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-ones 7 by means of the CuI/N,N-dimethylglycine-catalyzed intramolecular C–N bond formation reaction of 1-(2-bromobenzyl)azetidine-2-carboxamides 6. The efficient transformations of 7 into the diverse functionalized 1,4-benzodiazepine derivatives 9 through either N-methylation and the azetidine ring-opening reaction cascade or a straightforward reaction with methyl chloroformate are also presented. To the best of our knowledge, there is no precedent for the construction of azetidine-fused 1,4-diazepine derivatives and their application in the synthesis of 3-functionalized 1,4-benzodiazepine compounds.

2. Results and Discussion

We commenced our study with the examination of the intramolecular C–N bond coupling reaction of azetidine-2-carboxamides 6. The substrates 6 were prepared according to a known procedure in the literature [40,41]. As we expected, catalyzed by CuI/N,N-dimethylglycine (DMGC), azetidine-2-carboxamides 6a–d underwent the cross-coupling reaction smoothly to form the C–N bond efficiently under basic conditions. Thus, after refluxing in 1,4-dioxane for 3 h, fused heterocyclic ring products, 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-ones (7), were obtained in 91–98% yields (Scheme 2). It is worth noting that the aryl–Cl bond remained intact in the copper-catalyzed synthesis, remaining a useful handle for further chemical manipulations [42,43].
The resulting precursors 7 represent a unique type of 1,4-benzodiazepine compounds that contain a fused four-membered N-heterocyclic ring. Owing to the relatively high ring strain, azetidine is prone to the ring-opening reaction [44,45,46,47]. The selective opening of the azetidine ring of the precursors 7 would form 1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-ones or 1,3,4,5,6,7-hexahydro-2H-benzo[b][1,5]diazonin-2-ones. Our interest in the derivatization of 1,4-benzodiazepine compounds led us to explore the reactivity of compounds 7. However, the fused-ring precursors 7 were resistant to the ring-opening reaction, and their direct reactions with nucleophiles did not lead to any products. To facilitate the ring-opening reaction of azetidine, azetidines 7 were converted into the corresponding quaternary ammonium salts. After screening a variety of alkylating reagents, including methyl iodide, benzyl bromide, etc., we discovered that methyl triflate was a highly reactive reagent for the selective methylation reaction (Scheme 3). Upon treatment with two equivalents of methyl triflate under mild reaction conditions, compounds 7 were transformed almost quantitatively into ammonium triflates 8. No methylation on the amide moiety was observed because of the higher basicity of azetidine.
With ammonium salts in hand, we studied the ring-opening reaction of 8 with different nucleophiles. With compound 8d as the model substrate (Table 1), the opening of the azetidinium ring employing NaN3 as a nucleophile was surveyed. Pleasingly, the reaction of 8d with NaN3 in DMF at room temperature proceeded smoothly to afford 3-(2-azidoethyl)-4,8-dimethyl-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9da) (Nu = N3) in a 91% yield (entry 1, Table 1). As expected, replacement of the reaction medium from polar DMF to THF or DCM resulted in a slight decrease of both the reaction rate and the chemical yield (entries 2–3, Table 1). When KCN was used as the nucleophilic reagent, the corresponding ring-opening product 9db (Nu = CN) was obtained in a moderate yield under the same conditions (entry 4, Table 1), but the chemical yield could be improved to 78% by elongating the reaction time to 24 h (entry 5, Table 1). Sodium thiophenolate (PhSNa) acted as an excellent nucleophile to open the azetidinium ring of 8d to furnish the sulfide-bearing product 9dc in a nearly quantitative yield (entry 6, Table 1). It should be noted, however, that sodium phenoxide (PhONa) did not react with 8da, most probably due to its lower nucleophilicity in comparison with PhSNa (entries 7–10, Table 1). It is interesting to address the fact that, for the ring-opening reaction of 8, a nucleophilic attack on the azetidinium moiety always occurred at C3 rather than the C1 position. In other words, the reaction gave seven-membered heterocyclic products 8 instead of nine-membered ones, which has been confirmed unambiguously through the X-ray single crystal of 9aa (see Supporting Information). The superb regioselectivity was most likely attributable to the steric effect since methylene was more accessible by an attacking nucleophilic reagent than methine between the ammonium and carbonyl moieties.
The synthesis of functionalized 1,4-benzodiazepine derivatives by means of the selective azitidinium ring-opening reaction was readily extended to other substrates. As demonstrated in Scheme 4, all the substrates 8a–d reacted well with NaN3, KCN and PhSNa, affording a range of diverse functionalized 1,4-benzodiazepines derivatives in moderate to excellent yields within 6–24 h (Scheme 4). It was clear that NaN3 was the most powerful reactant, and the reaction proceeded most rapidly and efficiently to give excellent yields of products 9aa–ba and 9da. The sulfide-containing products 9ac and 9cc–dc were also obtained in very high yields using the reaction of 8 with PhSNa, albeit a slightly longer reaction period was required. In the case of KCN, the ring-opening reaction took 24 h to complete the formation of 9bb–db as the sole products. Due to the strong absorption on silica gel, they were isolated in a yield of 73–78% after silica gel column chromatography. The nature of the substituent on the benzene ring had virtually no influence on the outcomes of the ring-opening reaction, rendering the method applicable to the preparation of various substituted 1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one products.
Encouraged by the facile and selective reaction of the azetidinium ring in 8, we turned our attention to the reaction of 7 with acyl chlorides. It was envisaged that acylation on the nitrogen atom in azetidine 7 would further enhance the ring-opening reactivity of the resulting N-methoxycarbonyl azetidinium derivative [48,49,50]. To our delight, compounds 7a–d and methyl chloroformate in acetonitrile with reflux gave rise to the formation of 2-chloroethyl-substituted 1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one products. The complete and straightforward conversion of compounds 7 into products 9 indicated that the reaction proceeded efficiently the N-methoxycarbonylation, followed by the ring opening of the in situ generated N-methoxycarbonyl azetidinium derivatives by chloride anion (Scheme 5). The synthesis could be readily scaled up, as exemplified by the gram-scale synthesis of 9ad (Scheme 5).

3. Conclusions

In summary, we have provided a facile and efficient protocol to synthesize diverse functionalized 1,4-benzodiazepine derivatives using intramolecular C–N bond coupling and the successive ring-opening of azetidines. The easy availability of all the starting materials and the mild reaction conditions render the method versatile and useful for the preparation of novel and unique 1,4-benzodiazepine derivatives, which are in high demand for drug discovery and development.

4. Materials and Methods

4.1. General Information

All the chemicals were dried or purified according to standard procedures prior to use. The flash column chromatography was performed on silica gel (100–200). The reactions were monitored using pre-coated, glass-backed silica gel plates and visualized by means of UV irradiation (254 nm) or KMnO4. The 1H NMR and 13C NMR spectra were recorded on a Bruker AV500 spectrometer at ambient temperature. The chemical shifts are reported in ppm with either tetramethylsilane or the residual solvent resonance used as an internal standard. The high-resolution mass spectra (HRMS) were measured on a quadrupole tome-of-flight mass spectrometer (Q-TOF-MS) using electrospray ionization (ESI) as an ionization method. Crystallographic data were collected on a Rigaku XtaLAB Synergy (Cu) X-ray single crystal diffractometer. All the yields reported are the isolated yields.

4.2. General Procedure for the Synthesis of Compounds 6a–d

Step 1: To a flask (250 mL) equipped with a magnetic stirrer were added the corresponding 2-((2-bromobenzyl)(2-chloroethyl)amino)acetonitrile (50 mmol), potassium tert-butoxide (11.2 g, 100 mmol) and dry THF (100 mL). The reaction mixture was stirred at room temperature until the substrate disappeared and then saturated NH4Cl aqueous solution (50 mL) was added to quench the reaction. The mixture was concentrated in vacuo to remove the THF and the residue was extracted with ethyl acetate (4 × 50 mL) and washed with brine (1 × 50 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under a vacuum to give the crude product 1-(2-bromobenzyl)azetidine-2-carbonitrile, which was used immediately without further purification.
Step 2: Under slight heating and stirring, the product from the previous step was dissolved in tert-butanol (50 mL), and then anhydrous KOH (168 mg, 30 mmol) was added in portions. The resulting mixture was stirred at reflux until the substrate disappeared and water (20 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 × 50 mL), and washed with brine (2 × 50 mL). The organic layer was dried over anhydrous Na2SO4, and concentrated under a vacuum. The residue was chromatographed on a silica gel column eluted with a mixture of petroleum ether and ethyl acetate (3:1) to give pure product 6.
1-(2-Bromobenzyl)azetidine-2-carboxamide (6a). Light yellow solid (41% yield, 2 steps). m.p. 140–141 °C; IR (KBr) ν 3413.3, 1675.0 cm−1; 1H NMR (400 MHz, chloroform-d) δ 7.56 (d, J = 8.1 Hz, 1H), 7.32–7.25 (m, 2H), 7.23 (br s, 1H), 7.18–7.10 (m, 1H), 6.06 (br s, 1H), 3.82 (d, J = 12.9 Hz, 1H), 3.74 (t, J = 8.6 Hz, 1H), 3.64 (d, J = 13.0 Hz, 1H), 3.37–3.29 (m, 1H), 3.04 (q, J = 8.4 Hz, 1H), 2.47–2.39 (m, 1H), 2.24–2.12 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 176.2, 136.5, 133.1, 130.8, 129.2, 127.6, 124.5, 66.0, 62.0, 50.9, 23.1; HRMS (ESI) m/z [M + H]+ calcd. for C11H14BrN2O 269.0284, 271.0264; found 269.0291, 271.0270.
1-(2-Bromo-4-chlorobenzyl)azetidine-2-carboxamide (6b). Light yellow solid (36% yield, 2 steps). m.p. 146–147 °C; IR (KBr) ν 3398.2, 1674.9 cm−1; 1H NMR (400 MHz, chloroform-d) δ 7.60 (d, J = 1.6 Hz, 1H), 7.33–7.28 (m, 2H), 7.20 (br s, 1H), 5.83 (br s, 1H), 3.87–3.73 (m, 2H), 3.66 (d, J = 13.2 Hz, 1H), 3.42–3.32 (m, 1H), 3.05 (q, J = 8.3 Hz, 1H), 2.53–2.42 (m, 1H), 2.30–2.17 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 175.8, 135.1, 134.2, 132.8, 131.4, 127.9, 124.8, 66.0, 61.4, 51.0, 23.2; HRMS (ESI) m/z [M + H]+ calcd. for C11H13BrClN2O 302.9894, 304.9874; found 302.9889, 304.9869.
1-(2-Bromo-5-chlorobenzyl)azetidine-2-carboxamide (6c). Yellow solid (21% yield, 2 steps). m.p. 158–160 °C; IR (KBr) ν 3369.2, 1676.5 cm−1; 1H NMR (400 MHz, chloroform-d) δ 7.48 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 2.5 Hz, 1H), 7.18 (br s, 1H), 7.13 (dd, J = 8.5, 2.6 Hz, 1H), 5.76 (br s, 1H), 3.83–3.72 (m, 2H), 3.60 (d, J = 13.7 Hz, 1H), 3.42–3.35 (m, 1H), 3.07–2.98 (m, 1H), 2.51–2.41 (m, 1H), 2.27–2.16 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 175.7, 138.4, 134.1, 133.7, 130.3, 129.2, 122.1, 66.1, 61.7, 51.3, 23.2; HRMS (ESI) m/z [M + H]+ calcd. for C11H13BrClN2O 302.9894, 304.9874; found 302.9888, 304.9868.
1-(2-Bromo-4-methylbenzyl)azetidine-2-carboxamide (6d). Light yellow solid (22% yield, 2 steps). m.p. 135–137 °C; IR (KBr) ν 3414.2, 1667.5 cm−1; 1H NMR (400 MHz, chloroform-d) δ 7.36 (s, 1H), 7.19 (br s, 1H), 7.14 (d, J = 7.7 Hz, 1H), 7.07–7.01 (m, 1H), 6.20 (br s, 1H), 3.75 (d, J = 12.8 Hz, 1H), 3.68 (t, J = 8.6 Hz, 1H), 3.57 (d, J = 12.8 Hz, 1H), 3.32–3.24 (m, 1H), 2.99 (q, J = 8.4 Hz, 1H), 2.45–2.34 (m, 1H), 2.28 (s, 3H), 2.20–2.08 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 176.3, 139.3, 133.5, 133.3, 130.6, 128.3, 124.3, 65.9, 61.6, 50.7, 23.0, 20.7; HRMS (ESI) m/z [M + H]+ calcd. for C12H16BrN2O 283.0441, 285.0420; found 283.0448, 285.0427.

4.3. General Procedure for the Synthesis of Compounds 7a–d

Based on previous work [38], to a flask (50 mL) equipped with a magnetic stirrer were added compound 6 (1.0 mmol), CuI (0.4 mmol, 76 mg), DMGC (0.8 mmol, 112 mg), Cs2CO3 (2 mmol, 650 mg), and anhydrous 1,4-dioxane (34 mL) under argon protection. The reaction mixture was stirred at reflux for about 3 h until the substrate disappeared. After the reaction, ethyl acetate (100 mL) was added to dilute the mixture before filtration. The solvents were removed in vacuo and the residue was purified by flash column chromatography (PE:EA = 1:1) to afford products 7.
1,4,9,10a-Tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-one (7a). White solid (94% yield, 176.8 mg). m.p. 184–186 °C; IR (KBr) ν 3187.6, 1657.2 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.20 (br s, 1H), 7.29 (d, J = 7.4 Hz, 2H), 7.15 (t, J = 7.5 Hz, 1H), 7.00 (d, J = 7.7 Hz, 1H), 4.07 (dd, J = 7.8, 2.4 Hz, 1H), 3.79–3.66 (m, 2H), 3.56–3.41 (m, 2H), 2.69–2.60 (m, 1H), 2.49–2.37 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 173.0, 136.9, 130.4, 130.0, 129.0, 125.9, 121.7, 64.5, 56.7, 54.9, 19.6; HRMS (ESI) m/z [M + H]+ calcd. for C11H13N2O 189.1022; found 189.1028.
7-Chloro-1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-one (7b). White solid (93% yield, 206.5 mg). m.p. 192–192 °C; IR (KBr) ν 3177.6, 1624.2 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.26 (br s, 1H), 7.22 (d, J = 8.1 Hz, 1H), 7.13 (dd, J = 8.1, 2.0 Hz, 1H), 7.03 (d, J = 1.9 Hz, 1H), 4.07 (dd, J = 7.7, 2.4 Hz, 1H), 3.74–3.64 (m, 2H), 3.57–3.42 (m, 2H), 2.68–2.61 (m, 1H), 2.48–2.39 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 173.4, 138.3, 134.3, 131.1, 128.7, 125.8, 121.8, 64.5, 56.2, 54.9, 19.6; HRMS (ESI) m/z [M + H]+ calcd. for C11H12ClN2O 223.0633; found 223.0640.
6-Chloro-1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-one (7c). White solid (98% yield, 217.6 mg). m.p. 184–185 °C; IR (KBr) ν 3169.7, 1677.2 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.42 (br s, 1H), 7.29–7.23 (m, 2H), 6.98–6.93 (m, 1H), 4.05 (dd, J = 7.8, 2.7 Hz, 1H), 3.70 (d, J = 11.0 Hz, 1H), 3.62 (d, J = 11.0 Hz, 1H), 3.55–3.41 (m, 2H), 2.66–2.60 (m, 1H), 2.48–2.38 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 173.0, 135.5, 131.9, 131.0, 130.0, 128.9, 123.0, 64.5, 56.3, 54.9, 19.7; HRMS (ESI) m/z [M + H]+ calcd. for C11H12ClN2O 223.0633; found 223.0641.
7-Methyl-1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-one (7d). White solid (91% yield, 183.9 mg). m.p. 211–212 °C; IR (KBr) ν 3188.6, 1662.9 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.59 (br s, 1H), 7.15 (d, J = 7.7 Hz, 1H), 6.95 (d, J = 7.1 Hz, 1H), 6.81 (s, 1H), 4.05 (dd, J = 7.8, 2.4 Hz, 1H), 3.69 (d, J = 10.9 Hz, 1H), 3.64 (d, J = 10.9 Hz, 1H), 3.56–3.40 (m, 2H), 2.67–2.61 (m, 1H), 2.48–2.37 (m, 1H), 2.32 (s, 3H); 13C NMR (101 MHz, chloroform-d) δ 173.3, 138.9, 136.8, 129.8, 127.3, 126.5, 122.2, 64.4, 56.4, 54.8, 21.2, 19.6; HRMS (ESI) m/z [M + H]+ calcd. for C12H13N2O 203.1179; found 203.1172.

4.4. General Procedure for the Synthesis of Compounds 8a–d

To a flask (10 mL) equipped with a magnetic stirrer were added compound 7 (1.0 mmol) and anhydrous DCM (5 mL). After cooling to 0 °C, methyl triflate (0.22 mL, 2.0 mmol) was slowly added, and then the reaction mixture was stirred at room temperature for 1 h. The solvents were removed in vacuo and the residue was washed several times with a small amount of dry ether to afford products 8.
3-Methyl-10-oxo-2,3,4,9,10,10a-hexahydro-1H-azeto[1,2-a]benzo[e][1,4]diazepin-3-ium triflate (8a). White solid (98% yield, 345.0 mg). m.p. 167–167 °C; IR (KBr) ν 3229.8, 1692.5 cm−1; 1H NMR (400 MHz, acetonitrile-d3) δ 9.01 (br s, 1H), 7.59–7.52 (m, 1H), 7.45 (d, J = 7.3 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 4.91 (d, J = 13.3 Hz, 1H), 4.82 (dd, J = 9.3, 6.1 Hz, 1H), 4.56 (q, J = 10.0 Hz, 1H), 4.32–4.23 (m, 2H), 3.13–2.90 (m, 5H); 13C NMR (101 MHz, acetonitrile-d3) δ 165.7, 137.1, 133.1, 132.8, 126.8, 123.3, 122.3, 121.9 (q, J = 322.2 Hz, 1C), 74.3, 65.6, 62.9, 50.1, 18.8; HRMS (ESI) m/z [M-OTf]+ calcd. for C12H15N2O 203.1179; found: 203.1185.
7-Chloro-3-methyl-10-oxo-2,3,4,9,10,10a-hexahydro-1H-azeto[1,2-a]benzo[e][1,4]diazepin-3-ium triflate (8b). White solid (99% yield, 382.2 mg). m.p. 206–207 °C; IR (KBr) ν 3209.5, 1678.7 cm−1; 1H NMR (400 MHz, acetonitrile-d3) δ 9.01 (br s, 1H), 7.43 (d, J = 8.2 Hz, 1H), 7.36–7.24 (m, 2H), 4.92–4.79 (m, 2H), 4.55 (q, J = 9.9 Hz, 1H), 4.34–4.21 (m, 2H), 3.05 (s, 3H), 3.03–2.92 (m, 2H); 13C NMR (101 MHz, acetonitrile-d3) δ 165.6, 138.7, 137.8, 134.6, 126.8, 123.1, 122.0 (q, J = 323.2 Hz, 1C), 121.1, 74.4, 65.8, 62.4, 50.2, 18.8; HRMS (ESI) m/z [M-OTf]+ calcd. for C12H14ClN2O 237.0789; found: 237.0794.
6-Chloro-3-methyl-10-oxo-2,3,4,9,10,10a-hexahydro-1H-azeto[1,2-a]benzo[e][1,4]diazepin-3-ium triflate (8c). White solid (98% yield, 378.3 mg). m.p. 215–216 °C; IR (KBr) ν 3200.3, 1678.1 cm−1; 1H NMR (400 MHz, acetonitrile-d3) δ 9.05 (br s, 1H), 7.60–7.46 (m, 2H), 7.24 (d, J = 8.6 Hz, 1H), 4.94–4.79 (m, 2H), 4.57 (q, J = 9.9 Hz, 1H), 4.33–4.23 (m, 2H), 3.09 (s, 3H), 3.05–2.92 (m, 2H); 13C NMR (101 MHz, acetonitrile-d3) δ 165.5, 136.2, 132.64, 132.60, 131.3, 124.9, 124.0, 121.9 (q, J = 322.2 Hz, 1C), 74.4, 65.9, 62.3, 50.3, 18.8; HRMS (ESI) m/z [M-OTf]+ calcd. for C12H14ClN2O 237.0789; found: 237.0796.
3,7-Dimethyl-10-oxo-2,3,4,9,10,10a-hexahydro-1H-azeto[1,2-a]benzo[e][1,4]diazepin-3-ium triflate (8d). White solid (99% yield, 362.4 mg). m.p. 192–194 °C; IR (KBr) ν 3224.6, 1676.3 cm−1; 1H NMR (400 MHz, deuterium oxide) δ 7.40 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 5.09 (dd, J = 11.2, 6.3 Hz, 2H), 4.66 (q, J = 10.4 Hz, 1H), 4.46–4.38 (m, 1H), 4.38–4.32 (m, 1H), 3.23–2.99 (m, 5H), 2.41 (s, 3H); 13C NMR (101 MHz, acetonitrile-d3) δ 165.7, 143.6, 137.0, 132.9, 127.6, 123.5, 122.0 (q, J = 322.2 Hz, 1C), 119.4, 74.2, 65.4, 62.8, 50.0, 21.2, 18.7; HRMS (ESI) m/z [M-OTf]+ calcd. for C13H17N2O 217.1335; found: 217.1341.

4.5. General Procedure for the Ring-Opening Reaction of Compounds 8

To a flask (10 mL) equipped with a magnetic stirrer were added compound 8 (1.0 mmol), different nucleophiles (2 mmol) (NaN3, KCN and PhSNa) and dry DMF (5 mL). After the addition, the reaction mixture was stirred at room temperature until the substrate disappeared (for NaN3, about 6 h; for KCN, about 24 h; for PhSNa, about 12 h), and then water (5 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 × 10 mL), and the combined organic layers were washed with brine (1 × 20 mL) and dried over anhydrous Na2SO4. The solvents were removed in vacuo and the residue was purified by flash column chromatography (PE:EA = 1:1) to afford products 9.
3-(2-Azidoethyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9aa). White solid (97% yield, 237.8 mg). m.p. 106–107 °C; IR (KBr) ν 3180.8, 2104.3, 1680.3 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.33 (br s, 1H), 7.33–7.26 (m, 2H), 7.16 (t, J = 7.2 Hz, 1H), 6.99 (d, J = 7.7 Hz, 1H), 3.93–3.76 (m, 2H), 3.49–3.38 (m, 2H), 3.36–3.29 (m, 1H), 2.39 (s, 3H), 2.19–2.10 (m, 1H), 1.91–1.81 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.4, 137.3, 130.5, 129.0 (2C), 125.3, 120.7, 60.8, 58.1, 48.6, 39.5, 28.7; HRMS (ESI) m/z [M + H]+ calcd. for C12H16N5O 246.1349; found 246.1355.
3-(2-Azidoethyl)-8-chloro-4-methyl-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9ba). White solid (95% yield, 265.1 mg). m.p. 101–101 °C; IR (KBr) ν 3178.4, 2084.1, 1681.4 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.96 (br s, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.1, 1.9 Hz, 1H), 7.04 (d, J = 1.8 Hz, 1H), 3.85 (d, J = 13.9 Hz, 1H), 3.75 (d, J = 13.9 Hz, 1H), 3.50–3.39 (m, 2H), 3.38–3.30 (m, 1H), 2.38 (s, 3H), 2.20–2.08 (m, 1H), 1.90–1.80 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 173.0, 138.6, 134.3, 131.4, 127.4, 125.2, 120.7, 61.0, 57.5, 48.5, 39.3, 28.6; HRMS (ESI) m/z [M + H]+ calcd. for C12H15ClN5O 280.0960; found 280.0966.
3-(2-Azidoethyl)-4,8-dimethyl-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9da). White solid (91% yield, 235.8 mg). m.p. 105–107 °C; IR (KBr) ν 3168.7, 2081.9, 1681.5 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.04 (br s, 1H), 7.15 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 6.79 (s, 1H), 3.84 (d, J = 13.6 Hz, 1H), 3.74 (d, J = 13.6 Hz, 1H), 3.47–3.37 (m, 2H), 3.35–3.26 (m, 1H), 2.38 (s, 3H), 2.35 (s, 3H), 2.19–2.08 (m, 1H), 1.90–1.78 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.1, 139.2, 137.2, 130.4, 126.2, 125.9, 121.2, 60.7, 57.8, 48.7, 39.5, 28.6, 21.2; HRMS (ESI) m/z [M + H]+ calcd. for C13H18N5O 260.1506; found 260.1512.
3-(8-Chloro-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)propanenitrile (9bb). White solid (75% yield, 197.3 mg). m.p. 147–148 °C; IR (KBr) ν 3193.8, 2237.7, 1696.3 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.69 (br s, 1H), 7.20–7.09 (m, 2H), 7.02 (s, 1H), 3.85 (s, 2H), 3.33 (t, J = 5.9 Hz, 1H), 2.56–2.46 (m, 2H), 2.34 (s, 3H), 2.24–2.14 (m, 1H), 2.02–1.92 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.5, 138.0, 134.4, 131.5, 127.0, 125.3, 120.8, 119.6, 62.9, 57.6, 39.2, 25.1, 14.0; HRMS (ESI) m/z [M + H]+ calcd. for C13H15ClN3O 264.0898; found 264.0905.
3-(7-Chloro-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)propanenitrile (9cb). White solid (73% yield, 192.1 mg). m.p. 170–171 °C; IR (KBr) ν 3305.8, 2246.7, 1666.0 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.41 (br s, 1H), 7.30–7.27 (m, 1H), 7.22 (d, J = 2.1 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 3.90 (d, J = 14.6 Hz, 1H), 3.84 (d, J = 14.6 Hz, 1H), 3.33 (t, J = 6.7 Hz, 1H), 2.57–2.47 (m, 2H), 2.36 (s, 3H), 2.23–2.14 (m, 1H), 2.06–1.92 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.3, 135.4, 130.4, 130.2, 130.1, 129.0, 122.0, 119.7, 63.1, 57.8, 39.2, 25.2, 13.9; HRMS (ESI) m/z [M + H]+ calcd. for C13H15ClN3O 264.0898; found 264.0906.
3-(4,8-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)propanenitrile (9db). White solid (78% yield, 189.6 mg). m.p. 161–162 °C; IR (KBr) ν 3173.7, 2245.7, 1681.1 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.66 (br s, 1H), 7.11 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.81 (s, 1H), 3.95–3.74 (m, 2H), 3.27 (t, J = 6.5 Hz, 1H), 2.54–2.44 (m, 2H), 2.34 (s, 6H), 2.21–2.11 (m, 1H), 2.01–1.90 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.2, 139.1, 136.8, 130.2, 126.1, 125.5, 121.3, 119.8, 62.7, 57.7, 39.5, 25.2, 21.2, 13.9; HRMS (ESI) m/z [M + H]+ calcd. for C14H18N3O 244.1444; found 244.1438.
4-Methyl-3-(2-(phenylthio)ethyl)-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9ac). White solid (91% yield, 284.1 mg). m.p. 107–108 °C; IR (KBr) ν 3305.8, 1670.1 cm−1; 1H NMR (400 MHz, chloroform-d) δ 9.02 (br s, 1H), 7.31–7.19 (m, 5H), 7.16–7.08 (m, 2H), 7.00 (dd, J = 7.8, 2.7 Hz, 1H), 3.87–3.72 (m, 2H), 3.46 (td, J = 7.0, 3.5 Hz, 1H), 3.04–2.89 (m, 2H), 2.36 (d, J = 3.5 Hz, 3H), 2.25–2.15 (m, 1H), 1.95–1.83 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 173.0, 137.5, 136.4, 130.3, 129.1, 129.0 (2C), 128.8, 125.9, 125.1, 120.7, 62.6, 58.0, 39.6, 30.4, 29.1; HRMS (ESI) m/z [M + H]+ calcd. for C18H21N2OS 313.1369; found 313.1374.
7-Chloro-4-methyl-3-(2-(phenylthio)ethyl)-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9cc). White solid (91% yield, 314.9 mg). m.p. 129–130 °C; IR (KBr) ν 3316.9, 1659.2 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.34 (br s, 1H), 7.30 (d, J = 7.5 Hz, 2H), 7.25–7.22 (m, 4H), 7.15 (t, J = 7.2 Hz, 1H), 6.89 (d, J = 8.3 Hz, 1H), 3.80 (s, 2H), 3.47 (t, J = 6.9 Hz, 1H), 3.07–2.90 (m, 2H), 2.35 (s, 3H), 2.23–2.14 (m, 1H), 1.95–1.86 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.8, 136.3, 135.8, 130.7, 130.2 (2C), 129.3, 129.0, 128.8, 126.1, 121.9, 62.8, 57.6, 39.5, 30.4, 29.1; HRMS (ESI) m/z [M + H]+ calcd. for C18H20ClN2OS 347.0979; found 347.0972.
4,8-Dimethyl-3-(2-(phenylthio)ethyl)-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one (9dc). White solid (95% yield, 309.8 mg). m.p. 137–138 °C; IR (KBr) ν 3295.9, 1663.1 cm−1; 1H NMR (400 MHz, chloroform-d) δ 8.37 (br s, 1H), 7.30–7.27 (m, 2H), 7.24–7.17 (m, 2H), 7.15–7.09 (m, 2H), 6.95 (d, J = 7.8 Hz, 1H), 6.77 (s, 1H), 3.80 (d, J = 13.6 Hz, 1H), 3.72 (d, J = 13.5 Hz, 1H), 3.44 (t, J = 6.9 Hz, 1H), 3.04–2.87 (m, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 2.25–2.13 (m, 1H), 1.94–1.82 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 172.7, 138.9, 137.3, 136.5, 130.2, 129.1, 129.0, 126.1, 126.0, 125.9, 121.2, 62.5, 57.7, 39.7, 30.4, 29.1, 21.2; HRMS (ESI) m/z [M + H]+ calcd. for C19H23N2OS 327.1526; found 327.1533.

4.6. General Procedure for the Ring-Opening Reaction of Compounds 7

To a flask (25 mL) equipped with a magnetic stirrer were added compound 7 (1.0 mmol) and anhydrous CH3CN (10 mL).Then, methyl chloroformate (0.19 mL, 2.0 mmol) was added dropwise. After the addition, the reaction mixture was stirred at reflux for about 2 h until the substrate disappeared, and then saturated NaHCO3 aqueous solution (10 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 × 20 mL), and the combined organic layers were washed with brine (1 × 30 mL) and dried over anhydrous Na2SO4. The solvents were removed in vacuo and the residue was purified by flash column chromatography (PE:EA = 2:1) to afford products 9.
Methyl 3-(2-chloroethyl)-2-oxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepine-4- carboxylate (9ad). White solid (98% yield, 276.4 mg). m.p. 162–163 °C; IR (KBr) ν 3193.6, 1689.8, 1655.4 cm−1; 1H NMR (500 MHz, chloroform-d) δ 8.92 (br s, 1H), 7.33–7.17 (m, 2H), 7.07 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 7.9 Hz, 1H), 5.15 (d, J = 32.3 Hz, 1H), 4.57 (s, 1H), 4.35 (d, J = 15.5 Hz, 1H), 3.81–3.53 (m, 5H), 2.60 (d, J = 46.2 Hz, 1H), 2.30 (s, 1H).; 13C NMR (126 MHz, chloroform-d) δ 172.8, 156.2, 136.4, 129.6, 129.0, 128.1, 124.0, 120.1, 59.4, 53.3, 46.7, 41.2, 35.3; HRMS (ESI) m/z [M + H]+ calcd. for C13H16ClN2O3, 283.0844. Found: 283.0854.
Methyl 8-chloro-3-(2-chloroethyl)-2-oxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4] diazepine-4-carboxylate (9bd). White solid (98% yield, 309.7 mg). m.p. 166–168 °C; IR (KBr) ν 3184.6, 1693.5, 1660.2 cm−1; 1H NMR (500 MHz, chloroform-d) δ 9.11 (br s, 1H), 7.25–7.08 (m, 1H), 7.03 (d, J = 7.4 Hz, 2H), 5.18 (s, 1H), 4.57 (d, J = 31.3 Hz, 1H), 4.28 (d, J = 15.6 Hz, 1H), 3.69–3.63 (m, 5H), 2.65 (s, 1H), 2.31 (s, 1H); 13C NMR (126 MHz, chloroform-d) δ 173.2, 156.1, 155.6, 137.5, 134.3, 130.7, 130.2, 126.6, 124.0, 120.0, 59.5, 53.4, 46.3, 41.1, 35.2; HRMS (ESI) m/z [M + H]+ calcd. for C13H15Cl2N2O3, 317.0454. Found: 317.0462.
Methyl 7-chloro-3-(2-chloroethyl)-2-oxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4] diazepine-4-carboxylate (9cd). White solid (99% yield, 312.9 mg). m.p. 171–173 °C; IR (KBr) ν 3178.1, 1696.2, 1667.5 cm−1; 1H NMR (500 MHz, chloroform-d) δ 8.99 (br s, 1H), 7.22 (dd, J = 8.4, 2.2 Hz, 2H), 6.93 (d, J = 8.4 Hz, 1H), 5.16 (s, 1H), 4.56 (d, J = 37.7 Hz, 1H), 4.30 (d, J = 15.6 Hz, 1H), 3.70 (s, 3H), 3.68–3.57 (m, 2H), 2.65 (s, 1H), 2.32 (s, 1H); 13C NMR (126 MHz, chloroform-d) δ 172.8, 156.1, 135.0, 129.7, 129.4, 129.0, 128.8, 121.3, 59.4, 53.5, 46.5, 41.1, 35.2; HRMS (ESI) m/z [M + H]+ calcd. for C13H15Cl2N2O3, 317.0454. Found: 317.0463.
Methyl 3-(2-chloroethyl)-8-methyl-2-oxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4] diazepine-4-carboxylate (9dd). White solid (98% yield, 290.2 mg). m.p. 165–167 °C; IR (KBr) ν 3194.8, 1692.8, 1661.3 cm−1; 1H NMR (500 MHz, chloroform-d) δ 8.54 (br s, 1H), 7.13 (d, J = 25.1 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 6.76 (s, 1H), 5.23–5.01 (m, 1H), 4.54 (s, 1H), 4.33 (d, J = 15.4 Hz, 1H), 3.76–3.53 (m, 5H), 2.56 (d, J = 41.1 Hz, 1H), 2.32 (s, 4H); 13C NMR (126 MHz, chloroform-d) δ 172.5, 156.2, 139.1, 136.1, 129.5, 129.1, 125.2, 120.5, 59.4, 53.3, 46.6, 41.3, 35.3, 21.2; HRMS (ESI) m/z [M + H]+ calcd. for C14H18ClN2O3, 297.1000. Found: 297.1009.

4.7. General Procedure for the Scale-Up Synthesis of Compound 9ad

To a flask (100 mL) equipped with a magnetic stirrer were added compound 7a (5.0 mmol, 0.94 g, 1.0 equiv) and anhydrous CH3CN (50 mL).Then, methyl chloroformate (10.0 mmol, 0.95 mL, 2.0 equiv) was added dropwise. After the addition, the reaction mixture was stirred at reflux for about 2 h until the substrate disappeared, and then saturated NaHCO3 aqueous solution (50 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 × 80 mL), and the combined organic layers were washed with brine (1 × 200 mL) and dried over anhydrous Na2SO4. The solvents were removed in vacuo and the residue was purified by flash column chromatography (PE:EA = 2:1) to afford 1.35 g of target product 9ad in a 96% yield.

Supplementary Materials

The crystallographic data of 9aa and the NMR (1H, 13C) spectra of all the new compounds can be downloaded at https://www.mdpi.com/article/10.3390/molecules30092014/s1.

Author Contributions

Conceptualization, X.-M.W. and X.-M.X.; methodology, S.C., S.-L.D. and Q.L.; formal analysis, S.C. and Q.L.; investigation, S.C., S.-L.D. and X.-M.W.; resources, S.C. and Q.L.; writing—original draft preparation, K.S. and X.-M.X.; writing—review and editing, X.-M.W. and X.-M.X.; visualization, X.-M.X.; supervision, K.S., Q.L. and X.-M.X.; project administration, X.-M.X.; funding acquisition, X.-M.X. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (21901220); Shandong Provincial Natural Science Foundation (ZR2024MB079), Qingchuang Technology Support Program of University in Shandong Province (2023KJ244) and the Young Scholars Research Fund of Yantai University (HY19B06).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Acknowledgments

We also gratefully acknowledge the Key Laboratory of Chemical Engineering and Process of Shandong Province for their support.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Costantino, L.; Barlocco, D. Privileged Structures as Leads in Medicinal Chemistry. Curr. Med. Chem. 2006, 13, 65–85. [Google Scholar] [CrossRef] [PubMed]
  2. Landquist, J.K. Comprehensive Heterocyclic Chemistry; Katritzky, A.R., Rees, C.W., Eds.; Pergamon: Oxford, UK, 1984; Volume 1. [Google Scholar]
  3. Khan, I.; Anupama; Singh, B. 1,4-benzodiazepine: An overview of biological properties. Sci. Rev. Chem. Commun. 2015, 5, 13–20. [Google Scholar]
  4. Yet, L. (Ed.) Benzodiazepines. In Privileged Structures in Drug Discovery; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2018; pp. 15–58. [Google Scholar]
  5. Sternbach, L.H. The Benzodiazepine Story. J. Med. Chem. 1979, 22, 1–7. [Google Scholar] [CrossRef] [PubMed]
  6. Herrero, S.; García-López, M.T.; Herranz, R. Expedient One-pot Synthesis of Novel Chiral 2-Substituted 5-phenyl-1,4-Benzodiazepine Scaffolds from Amino Acid-derived Amino Nitriles. J. Org. Chem. 2003, 68, 4582–4585. [Google Scholar] [CrossRef]
  7. Hanley, D.F.; Pozo, M. Treatment of Satus Epilepticus with Midazolam in the Critical Care Setting. Int. J. Clin. Pract. 2000, 54, 30–35. [Google Scholar] [CrossRef]
  8. Selnick, H.G.; Liverton, N.J.; Baldwin, J.J.; Butcher, J.W.; Claremon, D.A.; Elliott, J.M.; Freidinger, R.M.; King, S.A.; Libby, B.E.; McIntyre, C.J.; et al. Class III Antiarrhythmic Activity in vivo by Selective Blockade of the Slowly Activating Cardiac Delayed Rectifier Potassium Current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5phenyl-1-(2,2,2-trifluoroethyl)-2,3-Dihydro-1Hbenzo[e][1,4]diazepin-3-yl]acetamide. J. Med. Chem. 1997, 40, 3865–3868. [Google Scholar]
  9. Hsu, M.C.; Schutt, A.D.; Holly, M.; Slice, L.W.; Sherman, M.I.; Richman, D.D.; Potash, M.J.; Volsky, D.J. Inhibition of HIV Replication in Acute and Chronic Infections in vitro by a TAT Antagonist. Science 1991, 254, 1799–1802. [Google Scholar] [CrossRef]
  10. Zahradník, I.; Minarovič, I.; Zahradníková, A. Inhibition of the Cardiac L-Type Calcium Channel Current by Antidepressant Drugs. J. Pharmacol. Exp. Ther. 2008, 324, 977–984. [Google Scholar] [CrossRef]
  11. Semple, G.; Ryder, H.; Rooker, D.P.; Batt, A.R.; Kendrick, D.A.; Szelke, M.; Ohta, M.; Satoh, M.; Nishiha, A.; Akuzawa, S.; et al. (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N’-(3-(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist. J. Med. Chem. 1997, 40, 331–341. [Google Scholar] [CrossRef]
  12. Leimgruber, W.; Stefanovic, V.; Schenker, F.; Karr, A.; Berger, J. Isolation and Characterization of Anthramycin, a New Antitumor Antibiotic. J. Am. Chem. Soc. 1965, 87, 5791–5793. [Google Scholar] [CrossRef]
  13. Hu, Y.; Phelan, V.; Ntai, I.; Farnet, C.M.; Zazopoulos, E.; Bachmann, B.O. Benzodiazepine Biosynthesis in Streptomyces refuineus. Chem. Biol. 2007, 14, 691–701. [Google Scholar] [CrossRef] [PubMed]
  14. Mohamed, L.W.; El-yamany, M.F. Design and Synthesis of Novel 1,4-Benzodiazepine Derivatives and Their Biological Evaluation as Cholinesterase Inhibitors. Arch. Pharmacol. Res. 2012, 35, 1369–1377. [Google Scholar] [CrossRef] [PubMed]
  15. Cheng, M.-F.; Yu, H.-M.; Ko, B.-W.; Chang, Y.; Chen, M.-Y.; Ho, T.-I.; Tsai, Y.-M.; Fang, J.-M. Practical Synthesis of Potential Endothelin Receptor Antagonists of 1,4-Benzodiazepine-2,5-dione Derivatives Bearing Substituents at the C3-, N1-and N4-Positions. Org. Biomol. Chem. 2006, 4, 510–518. [Google Scholar] [CrossRef] [PubMed]
  16. Kaur, N.; Kishore, D. Synthetic Strategies Applicable in the Synthesis of Privileged Scaffold: 1,4-Benzodiazepine. Synth. Commun. 2014, 44, 1375–1413. [Google Scholar] [CrossRef]
  17. Keating, T.A.; Armstrong, R.W. A Remarkable Two-Step Synthesis of Diverse 1,4-Benzodiazepine-2,5-diones Using the Ugi Four-Component Condensation. J. Org. Chem. 1996, 61, 8935–8939. [Google Scholar] [CrossRef]
  18. Huang, Y.; Khoury, K.; Chanas, T.; Dömling, A. Multicomponent Synthesis of Diverse 1,4-Benzodiazepine Scaffolds. Org. Lett. 2012, 14, 5916–5919. [Google Scholar] [CrossRef]
  19. Wang, Y.; Chen, M.; Ding, M.-W. A Simple and One-pot Synthesis of 2,3,4,5-Tetrasubstituted 4,5-dihydro-3H-1,4-Benzodiazepines. Tetrahedron 2013, 69, 9056–9062. [Google Scholar] [CrossRef]
  20. Nadin, A.; Sanchez Lopez, J.M.; Owens, A.P.; Howells, D.M.; Talbot, A.C.; Harrison, T. New Synthesis of 1,3-Dihydro-1,4-benzodiazepin-2(2H)-ones and 3-Amino-1,3-dihydro-1,4-benzodiazepin-2(2H)-ones:  Pd-Catalyzed Cross-Coupling of Imidoyl Chlorides with Organoboronic Acids. J. Org. Chem. 2003, 68, 2844–2852. [Google Scholar] [CrossRef]
  21. Xu, X.-M.; Chen, D.-M.; Wang, Z.-L. Recent Advances in Sulfenylation of C(sp3)-H Bond Under Transition Metal-Free Conditions. Chin. Chem. Lett. 2020, 31, 49–57. [Google Scholar]
  22. Liu, S.; Zhao, T.; Qu, J.; Wang, B. Expedient Synthesis of 1,4-Benzodiazepines via a Tandem Condensation/[1,5]-Hydride Transfer/Cyclization Process. Adv. Synth. Catal. 2018, 360, 4094–4098. [Google Scholar] [CrossRef]
  23. Nunewar, S.N.; Sangu, K.G.; Kotla, N.K.; Tangellamudi, N.D. Oxidative Dearomatization as a Strategy for a Facile, Metal-Free Synthesis of Vanillyl Benzodiazepines. ChemistrySelect 2020, 5, 10015–10021. [Google Scholar] [CrossRef]
  24. Wang, J.-Y.; Guo, X.-F.; Wang, D.-X.; Huang, Z.-T.; Wang, M.-X. A New Strategy for the Synthesis of 1,4-Benzodiazepine Derivatives Based on the Tandem N-Alkylation-Ring Opening-Cyclization Reactions of Methyl 1-Arylaziridine-2-carboxylates with N-[2-Bromomethyl(phenyl)]trifluoroacetamides. J. Org. Chem. 2008, 73, 1979–1982. [Google Scholar] [CrossRef] [PubMed]
  25. Jumde, V.R.; Cini, E.; Porcheddu, A.; Taddei, M. A Metal-Catalyzed Tandem 1,4-Benzodiazepine Synthesis Based on Two Hydrogen-Transfer Reactions. Eur. J. Org. Chem. 2015, 2015, 1068–1074. [Google Scholar] [CrossRef]
  26. Popp, T.A.; Uhl, E.; Ong, D.N.; Dittrich, S.; Bracher, F. A New Approach to Monoprotected 1,4-Benzodiazepines via a One-pot N-Deprotection/Reductive Cyclization Procedure. Tetrahedron 2016, 72, 1668–1674. [Google Scholar] [CrossRef]
  27. Mishra, J.K.; Garg, P.; Dohare, P.; Kumar, A.; Siddiqi, M.I.; Ray, M.; Panda, G. Amino Acid-based Enantiomerically Pure 3-substituted 1,4-Benzodiazepin-2-ones: A New Class of Anti-ischemic Agents. Bioorg. Med. Chem. Lett. 2007, 17, 1326–1331. [Google Scholar] [CrossRef]
  28. Massa, S.; Mai, A.; Artico, M. Syntheses of 3b,4,6,7-Tetrahydro-5h,9h-pyrazino [2,1-c] phyrolo [1,2-a] [1,4] benzodiazepine, A Valuable Precursor of Potential Central Nervous System Agents. Tetrahedron 1989, 45, 2763–2772. [Google Scholar] [CrossRef]
  29. Hone, N.D.; Wilson, W.; Reader, J.C. Solid Phase Synthesis of Tetrahydro-1,4-benzodiazepin-2-ones. Tetrahedron Lett. 2003, 44, 8493–8495. [Google Scholar] [CrossRef]
  30. Hamann, L.G.; Ding, C.Z.; Miller, A.V.; Madsen, C.S.; Wang, P.; Stein, P.D.; Pudzianowski, A.T.; Green, D.W.; Monshizadegan, H.; Atwal, K.S. Benzodiazepine-based Selective Inhibitors of Mitochondrial F1F0 ATP Hydrolase. Bioorg. Med. Chem. Lett. 2004, 14, 1031–1034. [Google Scholar] [CrossRef]
  31. Molteni, G.; Buttero, P.D. A One-Step Synthesis of Enantiopure 2-Substituted 4,5-Dihydro-1,4-benzodiazepine-3-ones via Intramolecular Azide Cycloaddition. Tetrahedron Asymmetry 2007, 18, 1197–1201. [Google Scholar] [CrossRef]
  32. Manick, A.D.; Duret, G.; Tran, D.N.; Berhal, F.; Prestat, G. Synthesis of 1,4-Benzodiazepinones and 1,4-Benzoxazepinones via Palladium-Catalyzed Amino and Oxyacetoxylation. Org. Chem. Front. 2014, 1, 1058–1061. [Google Scholar] [CrossRef]
  33. Zhang, Z.; Qin, Z.; Chang, W.; Li, J.; Fan, R.; Wu, X.; Guo, R.; Xie, X.; Zhou, L. Nicke-Catalyzed Decarboxylative Cyclization of Isatoic Anhydrides with Carbodiimides: Synthesis of 2,3-Dihydroquinazolin-4(1H)-ones. Adv. Synth. Catal. 2020, 362, 2864–2869. [Google Scholar] [CrossRef]
  34. Neukom, J.D.; Aquino, A.S.; Wolfe, J.P. Synthesis of Saturated 1,4-Benzodiazepines via Pd-Catalyzed Carboamination Reactions. Org. Lett. 2011, 13, 2196–2199. [Google Scholar] [CrossRef] [PubMed]
  35. Beccalli, E.M.; Broggini, G.; Paladino, G.; Penoni, A.; Zoni, C. Regioselective Formation of Six- and Seven-Membered Ring by Intramolecular Pd-Catalyzed Amination of N-Allyl-anthranilamides. J. Org. Chem. 2004, 69, 5627–5630. [Google Scholar] [CrossRef] [PubMed]
  36. Herrero, M.T.; Tellitu, I.; Dominguez, E.; Moreno, I.; SanMartin, R. A Novel and Efficient Iodine(III)-Mediated Access to 1,4-Benzodiazepin-2-ones. Tetrahedron Lett. 2002, 43, 8273–8275. [Google Scholar] [CrossRef]
  37. Li, X.; Yang, L.; Zhang, X.; Zhang, D.; Du, Y.; Zhao, K. Construction of 1,4-Benzodiazepine Skeleton From 2-(Arylamino)benzamides Through PhI(OAc)2-Mediated Oxidative C-N Bond Formation. J. Org. Chem. 2014, 79, 955–962. [Google Scholar] [CrossRef]
  38. Ghorai, M.K.; Shahi, C.K.; Bhattacharyya, A.; Sayyad, M.; Mal, A.; Wani, I.A.; Chauhan, N. Syntheses of Tetrahydrobenzodiazepines via SN2-Type Ring-Opening of Activated Aziridines with 2-Bromobenzylamine Followed by Copper-Powder-Mediated C-N Bond Formation. Asian J. Org. Chem. 2015, 4, 1103–1111. [Google Scholar] [CrossRef]
  39. Leng, D.-H.; Wang, D.-X.; Pan, J.; Huang, Z.-T.; Wang, M.-X. Highly Efficient and Enantioselective Biotransformations of Racemic Azetidine-2-carbonitriles and Their Synthetic Applications. J. Org. Chem. 2009, 74, 6077–6082. [Google Scholar] [CrossRef]
  40. Agami, C.; Couty, F.; Evano, G. A Straightforward Synthesis of Enantiopure 2-Cyano Azetidines from β-Amino Alcohols. Tetrahedron Asymmetry 2002, 13, 297–302. [Google Scholar] [CrossRef]
  41. Sulmon, P.; De Kimpe, N.; Schamp, N.; Tinant, B.; Declercq, J.-P. Synthesis of Azetidines From β-Chloro Imines. Tetrahedron 1988, 44, 3653–3670. [Google Scholar] [CrossRef]
  42. Wang, L.; Sullivan, G.M.; Hexamer, L.A.; Hasvold, L.A.; Thalji, R.; Przytulinska, M.; Tao, Z.-F.; Li, G.; Chen, Z.; Xiao, Z.; et al. Design, Synthesis, and Biological Activity of 5,10-Dihydro-dibenzo[b,e][1,4]diazepin-11-one-Based Potent and Selective Chk-1 Inhibitors. J. Med. Chem. 2007, 50, 4162–4176. [Google Scholar] [CrossRef]
  43. Hasvold, L.A.; Wang, L.; Przytulinska, M.; Xiao, Z.; Chen, Z.; Gu, W.Z.; Merta, P.J.; Xue, J.; Kovar, P.; Zhang, H.; et al. Investigation of Novel 7,8-Disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as Potent Chk1 Inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2311–2315. [Google Scholar] [CrossRef] [PubMed]
  44. Couty, F.; David, O.; Larmanjat, B.; Marrot, J. Strained Azetidinium Ylides: New Reagents for Cyclopropanation. J. Org. Chem. 2007, 72, 1058–1061. [Google Scholar] [CrossRef] [PubMed]
  45. Gaertner, V.R. Ring-opening Alkylations of 1,1-Dialkyl-3-substituted Azetidinium Cations. Substituent Entropy-controlled Strained Ring-chain Equilibria. J. Org. Chem. 1968, 33, 523–530. [Google Scholar] [CrossRef]
  46. Vargas-Sanchez, M.; Couty, F.; Evano, G.; Prim, D.; Marrot, J. 3-Aminopyrrolidines via Ring Rearrangement of 2-Aminomethylazetidines. Synthesis of (−)-Absouline. Org. Lett. 2005, 7, 5861–5864. [Google Scholar] [CrossRef]
  47. Ghorai, M.K.; Kumar, A.; Das, K. Lewis Acid-Mediated Unprecedented Ring-Opening Rearrangement of 2-Aryl-N-Tosylazetidines to Enantiopure (E)-Allylamines. Org. Lett. 2007, 9, 5441–5444. [Google Scholar] [CrossRef]
  48. Feng, B.; Tang, M.; Xiao, R.; Wang, Q.; Zhu, G.; Zhang, Z.; Yuan, Z.; Wang, Y. Photocatalytic Three-Component Reductive Coupling Synthesis of gem-Difluorohomoallyl Secondary Amines. J. Org. Chem. 2025, 90, 2118–2125. [Google Scholar] [CrossRef]
  49. Vargas-Sanchez, M.; Lakhdar, S.; Couty, F.; Evano, G. Reaction of Azetidines with Chloroformates. Org. Lett. 2006, 8, 5501–5504. [Google Scholar] [CrossRef]
  50. Ma, S.; Yoon, D.H.; Ha, H.-J.; Leeb, W.K. Preparation of Enantiopure 2-Acylazetidines and Their Reactions with Chloroformates. Tetrahedron Lett. 2007, 48, 269–271. [Google Scholar] [CrossRef]
Molecules 30 02014 g001
Figure 1. Representative 1,4-benzodiazepines with important biological activities.
Figure 1. Representative 1,4-benzodiazepines with important biological activities.
Molecules 30 02014 g001
Molecules 30 02014 g002
Figure 2. Synthetic strategies for the construction of 1,4-benzodiazepine derivatives.
Figure 2. Synthetic strategies for the construction of 1,4-benzodiazepine derivatives.
Molecules 30 02014 g002
Molecules 30 02014 sch001
Scheme 1. The rational design for the synthesis of functionalized 1,4-benzodiazepine derivatives.
Scheme 1. The rational design for the synthesis of functionalized 1,4-benzodiazepine derivatives.
Molecules 30 02014 sch001
Molecules 30 02014 sch002
Scheme 2. The intramolecular C–N cross-coupling reaction catalyzed by CuI/N,N-dimethylglycine.
Scheme 2. The intramolecular C–N cross-coupling reaction catalyzed by CuI/N,N-dimethylglycine.
Molecules 30 02014 sch002
Molecules 30 02014 sch003
Scheme 3. The methylation of 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]-diazepin-10(2H)-ones.
Scheme 3. The methylation of 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]-diazepin-10(2H)-ones.
Molecules 30 02014 sch003
Molecules 30 02014 sch004
Scheme 4. The ring-opening reaction of trifluoromethanesulfonyl salts 8 with different nucleophiles. Reaction conditions: compound 8 (1.0 mmol, 1.0 equiv), nucleophile (2.0 mmol, 2.0 equiv) and DMF (5.0 mL) were added, and then the mixture was stirred at room temperature. The isolated yields are given based on compound 8.
Scheme 4. The ring-opening reaction of trifluoromethanesulfonyl salts 8 with different nucleophiles. Reaction conditions: compound 8 (1.0 mmol, 1.0 equiv), nucleophile (2.0 mmol, 2.0 equiv) and DMF (5.0 mL) were added, and then the mixture was stirred at room temperature. The isolated yields are given based on compound 8.
Molecules 30 02014 sch004
Molecules 30 02014 sch005
Scheme 5. The ring-opening reaction of 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-ones 7 with methyl chloroformate. Reaction conditions: compound 7 (1.0 mmol, 1.0 equiv), methyl chloroformate (2.0 mmol, 2.0 equiv) and CH3CN (10 mL) were refluxed for 2 h. The isolated yields are given based on compound 7.
Scheme 5. The ring-opening reaction of 1,4,9,10a-tetrahydroazeto[1,2-a]benzo[e][1,4]diazepin-10(2H)-ones 7 with methyl chloroformate. Reaction conditions: compound 7 (1.0 mmol, 1.0 equiv), methyl chloroformate (2.0 mmol, 2.0 equiv) and CH3CN (10 mL) were refluxed for 2 h. The isolated yields are given based on compound 7.
Molecules 30 02014 sch005
Table 1. Optimization of the ring-opening reaction of trifluoromethanesulfonate 8d 1.
Table 1. Optimization of the ring-opening reaction of trifluoromethanesulfonate 8d 1.
Molecules 30 02014 i001
Entry Nucleophile
(2.0 equiv) 		Solvent T
(°C) 		t
(h) 		Yield 2
(%)
1NaN3DMFrt691
2NaN3THFrt1284
3NaN3DCMrt1262
4KCNDMFrt1264
5KCNDMFrt2478
6PhSNaDMFrt1295
7PhOHDMFrt24N.R. 3
8PhOHDMFreflux24trace
9PhONaDMFrt24N.R. 3
10PhONaDMFreflux24trace
1 Reaction conditions: compound 8d (1.0 mmol, 1.0 equiv), nucleophile (2.0 mmol, 2.0 equiv) and solvent (5.0 mL) were added, and then the mixture was stirred at the corresponding temperature. 2 Yield of isolated product. 3 No reaction.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Xu, X.-M.; Chen, S.; Duan, S.-L.; Wang, X.-M.; Liu, Q.; Sun, K. Synthesis of 1,4-Benzodiazepines via Intramolecular C–N Bond Coupling and Ring Opening of Azetidines. Molecules 2025, 30, 2014. https://doi.org/10.3390/molecules30092014

AMA Style

Xu X-M, Chen S, Duan S-L, Wang X-M, Liu Q, Sun K. Synthesis of 1,4-Benzodiazepines via Intramolecular C–N Bond Coupling and Ring Opening of Azetidines. Molecules. 2025; 30(9):2014. https://doi.org/10.3390/molecules30092014

Chicago/Turabian Style

Xu, Xin-Ming, Sen Chen, Shao-Lei Duan, Xiang-Min Wang, Qian Liu, and Kai Sun. 2025. "Synthesis of 1,4-Benzodiazepines via Intramolecular C–N Bond Coupling and Ring Opening of Azetidines" Molecules 30, no. 9: 2014. https://doi.org/10.3390/molecules30092014

APA Style

Xu, X.-M., Chen, S., Duan, S.-L., Wang, X.-M., Liu, Q., & Sun, K. (2025). Synthesis of 1,4-Benzodiazepines via Intramolecular C–N Bond Coupling and Ring Opening of Azetidines. Molecules, 30(9), 2014. https://doi.org/10.3390/molecules30092014

Article Metrics

Back to TopTop